AKR1B10
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Peptide ELISA: 1/8000. Western Blot: 0.03 - 0.1 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
0,5 mg/mL
Buffer
Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Díez-Dacal, Gayarre, Gharbi, Timms, Coderch, Gago, Pérez-Sala: "Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity." in: Cancer research, Vol. 71, Issue 12, pp. 4161-71, (2011) (PubMed).
Target
AKR1B10
(Aldo-Keto Reductase Family 1, Member B10 (Aldose Reductase) (AKR1B10))
AKR1B11 antibody, AKR1B12 antibody, ALDRLn antibody, ARL-1 antibody, ARL1 antibody, HIS antibody, HSI antibody, 2310005E10Rik antibody, Akr1b16 antibody, AKR antibody, AKR1B10 antibody, Akr1b10 antibody, aldo-keto reductase family 1 member B10 antibody, aldo-keto reductase family 1, member B10 (aldose reductase) antibody, aldo-keto reductase family 1 member B10-like 2 antibody, AKR1B10 antibody, Akr1b10 antibody, AKR1B10L2 antibody, LOC100585902 antibody, LOC100723118 antibody, LOC101107697 antibody
Background
ARK1B10 is a NADPH dependant enzyme with an ability to efficiently reduce aliphatic and aromatic aldehydes. A 316 A.A protein, AKR1B10 is a highly efficient retinal reductase constituting the first cytosolic NADP (H) dependent retinal reductase described in humans and is characterized by the presence of a novel NADP binding motif. Due to its ability to convert glucose to sorbitol, AKR1B10 may have a role in development of secondary diabetic complications. It is abundantly expressed in adrenal gland, small intestine and colon, with lower levels in liver, thymus, prostate, testis, and skeletal muscle and its levels are up regulated in certain cancers such as hepatocellular carcinoma.Synonyms: AKR1B11, ARL-1, Aldo-keto reductase family 1 member B10, Aldose reductase-like, Aldose reductase-related protein, Small intestine reductase